Epidemiology, Pathophysiology, and Symptomatology of Friedreich Ataxia

A Friedreich ataxia specialist discusses how the typical clinical presentation of Friedreich's Ataxia includes early onset with symptoms such as ataxia and sensory loss, while also examining the pathophysiology and incidence rate of the condition.

EP: 1.Friedreich Ataxia: Addressing Treatment Objectives and Comorbidities

EP: 2.Guidelines & FDA Approval of Novel Friedreich Ataxia Therapy

EP: 3.Engaging mFARS Scale to Monitor Friedreich Ataxia Progression

EP: 4.Managing Adverse Events in Novel Friedreich’s Ataxia Therapy

EP: 5.Examining Trial Data on Omaveloxolone Efficacy

EP: 6.Promising Therapy Approaches for Advanced Friedreich Ataxia

EP: 7.Friedreich Ataxia: Looking Forward at the Treatment Landscape

Now Viewing

EP: 8.Epidemiology, Pathophysiology, and Symptomatology of Friedreich Ataxia

EP: 9.Diagnosis of Friedreich Ataxia

EP: 10.Impact of Friedreich Ataxia on Quality of Life

EP: 11.Clinical Utility of the Modified Friedreich Ataxia Rating Scale

EP: 12.Comorbidities and Complications Associated With Friedreich Ataxia

EP: 13.Challenges Associated With Friedreich Ataxia

EP: 14.Future Considerations for Friedreich Ataxia

Video content above is prompted by the following:

• Describe the typical clinical presentation of FA in terms of age of onset, initial symptoms, and life expectancy?
• Can you summarize the pathophysiology and incidence rate of Friedreich's Ataxia (FA)? 

Related Videos

Related Content

Advertisement

May 19th 2025

FDA Clears First Blood Test for Early Detection of Alzheimer-Linked Amyloid Plaques

Cameron Santoro

The FDA cleared marketing for the first in vitro diagnostic device that tests blood to aid in diagnosing Alzheimer disease.

May 14th 2025

Quantitative Magnetic Resonance Outcomes Suggest Gene Therapy Slows DMD Progression

Rose McNulty

Delandistrogene moxeparvovec (Elevidys; Sarepta Therapeutics) appeared to protect muscle from progressive damage in patients with Duchenne muscular dystrophy (DMD) based on muscle quantitative magnetic resonance measures.

April 18th 2025

At-Home DMD Video Assessment Found Valid, Reliable

Rose McNulty

The remote measurement tool enables Duchenne muscular dystrophy (DMD) assessments through analysis of caregiver-recorded videos.

March 12th 2025

Coming Together to Ensure Neurological Treatment Access: Q&A With Kavita V. Nair, PhD

Christina Mattina Kavita V. Nair, PhD

In 2025, each issue of Population Health, Equity & Outcomes will feature a profile of a health system leader transforming care in their area of expertise. This issue spotlights a conversation with Kavita V. Nair, PhD, of the University of Colorado Anschutz Medical Campus.

February 26th 2025

Adaptive Deep Brain Stimulation Technology Receives FDA Approval for Parkinson Disease

Giuliana Grossi

The FDA approves BrainSense Adaptive deep brain stimulation and electrode identifier technology for the treatment of Parkinson disease.

February 14th 2025

Adults With DMD More Than Twice as Likely to Experience Fractures

Rose McNulty

Less than half of patients had undergone bone monitoring, suggesting a need for better clinical guidance and management of osteoporosis in adult men with Duchenne muscular dystrophy (DMD).

Related Content

Advertisement

May 19th 2025

FDA Clears First Blood Test for Early Detection of Alzheimer-Linked Amyloid Plaques

Cameron Santoro

The FDA cleared marketing for the first in vitro diagnostic device that tests blood to aid in diagnosing Alzheimer disease.

May 14th 2025

Quantitative Magnetic Resonance Outcomes Suggest Gene Therapy Slows DMD Progression

Rose McNulty

Delandistrogene moxeparvovec (Elevidys; Sarepta Therapeutics) appeared to protect muscle from progressive damage in patients with Duchenne muscular dystrophy (DMD) based on muscle quantitative magnetic resonance measures.

April 18th 2025

At-Home DMD Video Assessment Found Valid, Reliable

Rose McNulty

The remote measurement tool enables Duchenne muscular dystrophy (DMD) assessments through analysis of caregiver-recorded videos.

March 12th 2025

Coming Together to Ensure Neurological Treatment Access: Q&A With Kavita V. Nair, PhD

Christina Mattina Kavita V. Nair, PhD

In 2025, each issue of Population Health, Equity & Outcomes will feature a profile of a health system leader transforming care in their area of expertise. This issue spotlights a conversation with Kavita V. Nair, PhD, of the University of Colorado Anschutz Medical Campus.

February 26th 2025

Adaptive Deep Brain Stimulation Technology Receives FDA Approval for Parkinson Disease

Giuliana Grossi

The FDA approves BrainSense Adaptive deep brain stimulation and electrode identifier technology for the treatment of Parkinson disease.

February 14th 2025

Adults With DMD More Than Twice as Likely to Experience Fractures

Rose McNulty

Less than half of patients had undergone bone monitoring, suggesting a need for better clinical guidance and management of osteoporosis in adult men with Duchenne muscular dystrophy (DMD).